Envona Powder for Solution for Infusion
Fosaprepitant (as dimeglumine)
150 mg
Boston Oncology Arabia
| Pack size | 10 Vial (10 ml) |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 28.62 AED |
Indications
Envona Powder for Solution for Infusion is used for:
For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Fosaprepitant (as dimeglumine) :
Mechanism of Action
Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with Aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that Aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid
ethasone and inhibits both the acute and delayed phases of cisplatin induced emesis.
In summary, the active form of fosaprepitant is as an NK1 antagonist which is because it blocks signals given off by NK1 receptors. This therefore decreases the likelihood of vomiting in patients experiencing.
Note
Envona 150 mg Powder for Solution for Infusion manufactured by Boston Oncology Arabia. Its generic name is Fosaprepitant (as dimeglumine). Envona is availble in Saudi Arabia.
Farmaco SA drug index information on Envona Powder for Solution for Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.